First published online
February 20, 2008, 10.2967/jnumed.107.044750
Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up
Eveline Boucher1,
Guillaume Bouguen1,
Etienne Garin2,
Anne Guillygomarch3,
Karim Boudjema4 and
Jean-Luc Raoul1
1 Département d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France; 2 Département d'Imagerie Médicale, Centre Eugène Marquis, Rennes, France; 3 Service Des Maladies du Foie, CHRU Pontchaillou, Rennes, France; and 4 Département de Chirurgie Viscérale et de Transplantation Hépatique, CHRU Pontchaillou, Rennes, France

View larger version (9K):
[in this window]
[in a new window]
|
FIGURE 1. Frequency and date of onset (years) of recurrences in control group (n = 28 [white bars]) and in 131I-lipiodol group (n = 28 [black bars]).
|
|

View larger version (7K):
[in this window]
[in a new window]
|
FIGURE 3. Overall survival of patients receiving a single 131I-lipiodol postoperative injection or surgery alone (not statistically significant). Lip = lipiodol.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
FIGURE 4. CT scans of 2 patients showing slight 131I-lipiodol retention 7 d after 131I-lipiodol injection.
|
|
Copyright © 2008 by the Society of Nuclear Medicine.